$IBRX is definitely showing potential. It reminds me of the way $AMAM climbed from $4 all the way to $28—just a steady, daily creep of a few cents on low volume until it really took off.
$IBRX – Someone mentioned $AMAM today, and it reminded me: I was an early believer in their drug (back when it was trading as $AMAM). I accumulated shares at an average cost around $5 and sold near $27.
Moral of the story? Do your own due diligence (DYODD), tune out the daily price noise/volatility, hold strong through the ups and downs—and if the thesis plays out, you can get rewarded handsomely. Patience pays in biotech. GLTL
$HCTI 😳 Seeing that “barcode” compression again at the trendline like last time? History loves to rhyme.
Back when $HCTI was sub-$0.02, it barcoded—everyone wrote it off—then BOOM to $0.08. Now it's barcoding at the bottom of the rising channel, right where buyers historically step in.
Look at similar setups in fellow microcaps:
$AMAM surged 100%+ off its trendline after buyout buzz.
$VRAX printed a bullish hammer setup at channel support before reversing up.
ChartMill
Add upcoming catalysts (CIO Conclave on Aug 22 + Nasdaq compliance on Aug 28) and you get textbook rocket fuel setup. Thin float & compressed price = massive delta when volume hits.
$HCTI is still undervalued, distorted by market noise—not fundamentals. If you missed last run, this is the clean re-entry point.
@Thesenutz8 No patience? WTH? I was patient with the sister here, $AMAM, held through major dips and a r/s, and it paid off big when they got bought out. I bought in here with the intent of holding for years while they work on their trials and hope for a buyout, too, or huge success on their own. When you see such inept management it makes one sick. EVERY PR or white paper, or bit of good news is followed up with an Offering within hours to knock it back down. They wont won’t even let this roll for 10 days to avoid delisting.
@Thesenutz8 I made serious bank on their sister, $AMAM, so jumped in here with a portion of the profits. This thing is just a turd in comparison, I didn’t trust $AMAM management, but they helped my fill my account. Now still don‘t trust remaining management, but will allow them years and years to deliver. Don‘t need no preaching, brother. Well aware of this apparent scam.
@premarketmaker Nope. Continuing to hold for the same reasons I held the sister company, $AMAM, or just flat out success for company. Made serious bank on that one, held through major ups and downs, and r/s. Hold for years, her. I did purge a bunch of garbage in my account last fall and jumped into AI and QC issues that paid off nicely so far, but HODL here. GL
$IBRX that was then most experts like you kept telling us for more than a year that buying and holding $AMAM was a disaster but, some of us noobs kept buying low $3s with conviction and sold for $27. somehow I believe ImmunityBio is worth more than $3B you know why I know? Because I heard it from PSS (spent $3B he said) so $30B is to low of a MC IMO, the right MC should be $65B
@Keluppar that is my current thinking, yes. But it's my own thinking and observations, and I have no insider information or special connections. I have been most curious as to why the ex CEO of Ambrx $AMAM has been following the posts by Dr. Stergiou on LinkedIn for some time.
@UpWeGo11 @MKRReformed @DaRealMonopolyGuy $AMAM was another one that went from sub .50 cents to $28 when they got bought up by $JNJ ... That was a good day 🙂
